- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| ALAMAR BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 09.06. | Stifel reiterates Buy rating on Alamar Biosciences stock at $28 | 1 | Investing.com | ||
| 02.06. | Alamar Biosciences, Inc.: Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics | 416 | GlobeNewswire (Europe) | NULISA DBS Extraction Kit recovers proteins from dried blood spot and dried plasma spot microsamples collected on leading third-party remote sampling devices
Workflow extends NULISA into longitudinal... ► Artikel lesen | |
| 12.05. | TD Cowen initiates Alamar Biosciences stock with buy rating | 12 | Investing.com | ||
| 12.05. | JPMorgan initiates Alamar Biosciences stock with overweight rating | 1 | Investing.com | ||
| 12.05. | Stifel initiates Alamar Biosciences stock with buy rating | 2 | Investing.com | ||
| 08.05. | Alamar Biosciences, Inc. GAAP EPS of -$1.74, revenue of $26M | 1 | Seeking Alpha | ||
| 08.05. | Alamar Biosciences, Inc.: Alamar Biosciences Reports First Quarter 2026 Financial Results | 413 | GlobeNewswire (Europe) | FREMONT, Calif., May 08, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today reported... ► Artikel lesen | |
| 08.05. | Alamar Biosciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 08.05. | Alamar Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Cathie Wood Is Buying Up Alamar Biosciences Stock After Its IPO. Should You Snag Proteomics-Focused ALMR Too? | 17 | Barchart.com | ||
| 21.04. | Alamar lists on Nasdaq, giving Qiming its fifth IPO in 2026 | 2 | KrASIA | ||
| 20.04. | Alamar Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 20.04. | Alamar Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.04. | Cathie Wood's Ark Invest buys proteomics company Alamar, Netflix; trims crypto names | 7 | Seeking Alpha | ||
| 20.04. | Qiming Venture Partners: Precision Proteomics Leader Alamar Biosciences Lists on NASDAQ | 479 | PR Newswire | SHANGHAI, April 20, 2026 /PRNewswire/ -- Alamar Biosciences, a portfolio company of Qiming Venture Partners and a global leader in precision proteomics, successfully listed on the NASDAQ... ► Artikel lesen | |
| 17.04. | Proteomics firm Alamar climbs 40% after upsized IPO | 1 | Seeking Alpha | ||
| 17.04. | Proteomics firm Alamar prices upsized IPO at $17 per share | 1 | Seeking Alpha | ||
| 17.04. | Protein biomarker detection platform Alamar Biosciences prices upsized IPO at $17, the high end of the range | 1 | Renaissance Capital | ||
| 17.04. | Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | 591 | AFX News | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen | |
| 15.04. | Alamar Biosciences, Inc. - 8-A12B, Registration of securities | - | SEC Filings |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 132,86 | +0,23 % | Apogee Therapeutics vor Übernahme: sharedealsPlus-Tipp wird zum Multibagger | Nachdem wir die Aktie von Apogee Therapeutics bereits im vergangenen Jahr zu Preisen von rund 40 US$ als heißen Buyout-Kandidaten vorgestellt hatten und sich ihr Kurs zwischenzeitlich mehr als verdoppeln... ► Artikel lesen | |
| QIAGEN | 32,610 | +1,73 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum zweiten Quartal auf "Buy" belassen. Diese dürften sich im Rahmen der eigenen Vorgaben des Diagnostikspezialisten... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,400 | +1,56 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| ADITXT | 0,040 | +105,73 % | Aditxt (ADTX) Stock Is Falling After Hours: What Is Going On? | ||
| TANGO THERAPEUTICS | 28,450 | -0,18 % | Tango Therapeutics, Inc.: Tango Therapeutics Appoints Robert Azelby to Board of Directors | BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 97,29 | -2,17 % | Kymera Therapeutics (KYMR) Soars 10.0%: Is Further Upside Left in the Stock? | ||
| BOUNDLESS BIO | 2,550 | +82,14 % | Boundless Bio, Inc.: Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement | Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency Serapha's lead program SERP-01 targets the... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,280 | -6,33 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,280 | 0,00 % | Bernstein hebt Kursziel für Summit Therapeutics Aktie aufgrund von Studienaussichten an | ||
| TARSUS PHARMACEUTICALS | 64,79 | +1,94 % | Tarsus Pharmaceuticals, Inc: Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease | - A pioneering investigational oral prophylactic approach designed to kill Lyme-infected ticks before disease transmission - IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 302,50 | -0,29 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 48,030 | +4,50 % | Hedge Fund and Insider Trading News: John Paulson, Warren Buffett, Ray Dalio, Brevan Howard, Rokos Capital Management, Noble Corp PLC (NE), Enliven Therapeutics Inc (ELVN), and More | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 21,530 | -2,84 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Proposed Public Offering | ZUG, Switzerland, June 22, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and... ► Artikel lesen | |
| ERASCA | 15,080 | 0,00 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| VERA THERAPEUTICS | 37,810 | -1,61 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen |
Das Unternehmen ALAMAR BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +0,44 % bei einem Aktienkurs von 22,880 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALAMAR BIOSCIENCES INC finden Sie auf Wallstreet Online.